Skip to main content

Table 3 Efficacy analysis

From: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

 

Phase 2

Validation

14 days intention-to-treat

  

No. of events/no. of patients at risk

55/299

101/884

Lethality rate, % (97.5% CI)

18.4% (13.6–24.0)

11.4% (9.1–14.0)

P value (P0 = 20%)

0.52

 < 0.001

14 days modified intention-to-treat

  

No. of events/no. of patients at risk

28/180

56/515

 Lethality rate, % (95% CI)

15.6% (10.6–21.7)

10.9% (8.3–13.9)

30 days intention-to-treat

  

No. of events/No. of patients at risk

67/299

158/858

 Lethality rate, % (97.5% CI)

22.4% (17.2–28.3)

18.4% (15.5–21.6)

 P value (P0 = 35%)

 < 0.001

 < 0.001

 Median time of death, days (IQR)

8 (4–14)

11 (4–18)

30 days modified intention-to-treat

  

No. of events/no. of patients at risk

36/180

99/495

 Lethality rate, % (95% CI)

20.0% (14.4–26.6)

20.0% (16.6–23.8)